Numerous studies have confirmed the engagement of VGCCs in age‐related disease, including Parkinson disease (Cav1.3) (Zamponi et al., 2015), ataxia (Cav2.1) (Dorgans et al., 2017), Alzheimer's disease (Cav3.1) (Rice et al., 2014). This evidence concerns the gene CACNA1A and early-onset autosomal dominant Alzheimer disease.